No Data
SHIONOGI & CO To Carry Out 3-for-1 Stock Split On September 27th, 2024
SHIONOGI & CO To Carry Out 3-for-1 Stock Split On September 27th, 2024
Jefferies Initiates SHIONOGI & CO(SGIOF.US) With Hold Rating, Announces Target Price $48.18
Viiv's Dovato as Effective as Gilead' Biktarvy for HIV but With Less Weight Gain
SHIONOGI & CO To Go Ex-Dividend On September 27th, 2024 With 0.748 USD Dividend Per Share And 3-for-1 Stock Split
FunPep - 1Q concludes an option agreement with Shionogi Pharmaceutical regarding the antibody-inducing peptide “FPP004X”
FunPep ＜4881＞ announced consolidated financial results for the 1st quarter (January to March 24) of the fiscal year ending 2024/12 on the 13th. Sales increased 54.8% from the same period last year to 50 billion yen, operating loss was 183 million yen (loss of 378 million yen in the same period last year), ordinary loss was 170 million yen (loss of 343 million yen), and quarterly net loss attributable to parent company shareholders was 168 million yen (341 million yen). About the antibody-inducing peptide project, the antibody-inducing peptide “FPP003” (label
No Data
No Data